Sodium Phenylbutyrate-Taurursodiol Promising for ALS

THURSDAY, Sept. 3, 2020 -- For patients with amyotrophic lateral sclerosis (ALS), function declines more slowly through 24 weeks in those receiving sodium phenylbutyrate-taurursodiol versus placebo, according to a study published in the Sept. 3...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: ALS | Pharmaceuticals | Sodium | Study